四环医药(00460)：安奈拉唑钠肠溶片(安久卫)治疗反流性食管炎中国III期临床试验完成全部受试者入组

Core Viewpoint - The announcement highlights the successful completion of patient enrollment for a Phase III clinical trial of Anaprazole Sodium Enteric-Coated Tablets (brand name: Anjiewei®) for the treatment of adult reflux esophagitis (RE) in China, involving 500 participants [1] Group 1: Clinical Trial Details - The Phase III clinical trial is a multi-center, randomized, double-blind, parallel-group study designed to evaluate the efficacy and safety of Anaprazole Sodium Enteric-Coated Tablets in adult patients with reflux esophagitis in China [1] - The primary clinical endpoint is the cure rate of reflux esophagitis as assessed by endoscopy compared to a positive control drug after an 8-week treatment period [1] - Secondary endpoints include the cure rate at week 4, changes in the severity and frequency of primary symptoms (heartburn and regurgitation) from baseline at weeks 4 and 8, and various efficacy metrics [1] Group 2: Safety Indicators - Safety indicators focus on the types, incidence, and severity of adverse events occurring during the trial [1]